These observations were at variance with much more favourable recent reports on synergistic effects of TRAIL and IR in breast and colon carcinoma cell lines (Chinnaiyan et al, 2000; Ravi et al, 2001) as well as Jurkat cells (Gong and Almasan, 2000; Kim et al, 2001a).
However, significant differences were observed in the "Professional teacher development in ICT" dimension depending on the degree programme (Early Childhood or Primary), with more favourable assessments reported by the first group.
If our results prove to be valid, then the incremental cost-effectiveness ratio of APC may be more favourable than reported in recent publications [ 11- 13].
We therefore believe that a higher proportion of patients diagnosed through screening (FOBT or colonoscopy in asymptomatic patients) would represent a higher diagnostic quality, since the therapeutic approach and, consequently, the patients' outcome (in terms of recurrence and survival) would be more favourable, as reported in the literature.
A systematic review illustrated that the prognosis of LBP reported in Australian studies was more favourable than those reported from Europe and the United States [ 6], but outcome measures differed and direct comparisons of the prognosis of LBP across countries are, to the best of our knowledge, non-existent.
The spectrum of non-haematological toxicity was comparable with that previously reported for bevacizumab in this patient population (Friedman et al, 2009) and appeared more favourable than that reported for bevacizumab plus irinotecan.
We hypothesised that there would be a positive relationship between higher NZDQI-A scores calculated from the FQ and more favourable nutrient intakes reported by the 4DFRs.
Recent Phase II studies comparing nintedanib and sorafenib as first-line monotherapy in patients with hepatocellular carcinoma (HCC) showed similar efficacy between the treatments in both Asian and European patient populations (Cheng et al, 2015; Palmer et al, 2015) with a more favourable safety profile reported for nintedanib in Asian patients (Cheng et al, 2015).
The baseline characteristics of the cohort indicate that this study population is typical of patients with locally advanced pancreatic cancer, and, in particular, sex, age, and performance status were not more favourable than those reported in other recent studies (Blackstock et al, 2003; Rich et al, 2004).
At comparable dose levels, Epirubicin is significantly less cardiotoxic than Doxorubicin (Perez et al, 1991) and Paclitaxel seems to play a minor role on Epirubicin metabolism when the two drugs are used in combination (Conte et al, 1997, Danesi et al, 2002); this data could explain, in part, the more favourable cardiotoxic profile reported for the douplet Paclitaxel/Epirubicin.
